A year after Hong Kong’s stock listing overhaul, city’s aim to be Asia’s biotech hub is still a work in progress

That is six and a half times more than the amount raised from biotech IPOs in the corresponding period a year earlier, according to data from Refinitiv. In terms of funds raised, Hong Kong’s main …
( read original story …)

---